{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:08:48Z","timestamp":1761898128778,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The aim of this study was to assess the safety and effectiveness of abciximab (ReoPro\u00ae), a glycoprotein-IIb\/IIIa receptor antagonist, in the management of thromboembolic complications during endovascular treatment of intracranial aneurysms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From an inhouse data base of 218 coil embolisations in 178 patients with cerebral aneurysms (median age 57\u202fyears, 72% females)\u2013among them 53 interventions with subarachnoid hemorrhage (SAH) requiring acute endovascular treatment, and 165 with elective endovascular treatment of unruptured aneurysms - we retrospectively reviewed 53 interventions that received abciximab during endovascular treatment, and diffusion-weighted imaging after endovascular treatment (median 7\u202fdays after intervention, range 5 to 9\u202fdays). Four subgroups were identified, (i) SAH patients with abciximab (SAH-Ab, <jats:italic>n<\/jats:italic>\u202f=\u202f18), (ii) SAH patients without abciximab (SAH-no, <jats:italic>n<\/jats:italic>\u202f=\u202f35), (iii) elective patients with abciximab (El-Ab, <jats:italic>n<\/jats:italic>\u202f=\u202f31), and (iv) elective patients without abciximab (El-no, <jats:italic>n<\/jats:italic>\u202f=\u202f134) treatment. Angiographic success of clot dissolution, post-interventional occurrence of intracranial hemorrhages and the modified Rankin Scale (mRS) pre and 6\u202fmonths after endovascular treatment were recorded. Brain tissue infarction-load was categorized as: no, punctual (&amp;lt;500\u202fmm<jats:sup>2<\/jats:sup>), small (500\u20131,000\u202fmm<jats:sup>2<\/jats:sup>) and large (&amp;gt;1,000\u202fmm<jats:sup>2<\/jats:sup>) infarctions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Complete and partial angiographic success was achieved in 94% of cases. No significant differences in infarction-loads were found between SAH-Ab and SAH-no, or El-Ab and El-no subgroups. Abciximab use was not associated with increased infarction-loads or worse mRS scores. Hunt &amp;amp; Hess score at admission significantly predicted both infarction-loads (<jats:italic>\u03b2<\/jats:italic>\u202f=\u202f0.38, <jats:italic>p<\/jats:italic>\u202f=\u202f0.02) and 6-month mRS (<jats:italic>\u03b2<\/jats:italic>\u202f=\u202f0.75, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) in SAH patients. Two patients experienced post-interventional hemorrhages: one small bleed near the extraventricular drain in in the SAH-Ab group, and one large hemorrhage due to wire perforation in the El-Ab group. No fatal hemorrhages occurred following abciximab administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Abciximab was safe and seemed effective for the management of thromboembolic complications during endovascular treatment of intracranial aneurysms, without increasing infarct burden or compromising functional outcomes in affected patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1573247","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T04:10:27Z","timestamp":1750824627000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Abciximab in rescue therapy of thromboembolic events during endovascular treatment of cerebral aneurysms: single center experience of 49 cases"],"prefix":"10.3389","volume":"16","author":[{"given":"Lukas","family":"Lenhart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Ladenhauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Rass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie A.","family":"Treichl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronny","family":"Beer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian F.","family":"Freyschlag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke R.","family":"Gizewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid E.","family":"Grams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1161\/strokeaha.108.539197","article-title":"Abciximab is a safe rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization: single center experience in 42 cases and review of the literature","volume":"40","author":"Ries","year":"2009","journal-title":"Stroke"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/neuros\/nyx170","article-title":"Glycoprotein IIb\/IIIa inhibitors in prevention and rescue treatment of thromboembolic complications during endovascular embolization of intracranial aneurysms","volume":"82","author":"Dornbos","year":"2018","journal-title":"Neurosurgery"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3174\/ajnr.A4066","article-title":"Rescue treatment of thromboembolic complications during endovascular treatment of cerebral aneurysms: a meta-analysis","volume":"36","author":"Brinjikji","year":"2015","journal-title":"Am J Neuroradiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/neurintsurg-2015-011935","article-title":"Intraprocedural abciximab bolus versus pretreatment oral dual antiplatelet medication for endovascular stenting of unruptured intracranial aneurysms","volume":"8","author":"Levitt","year":"2016","journal-title":"J Neurointerv Surg"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1177\/1591019915582001","article-title":"Safety of Abciximab injection during endovascular treatment of ruptured aneurysms","volume":"21","author":"Gentric","year":"2015","journal-title":"Interv Neuroradiol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.ijcard.2016.07.213","article-title":"How abciximab might be clinically useful","volume":"222","author":"Usta","year":"2016","journal-title":"Int J Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jnis.2009.001933","article-title":"Intra-arterial abciximab for the treatment of thrombus formation during coil embolization of intracranial aneurysms","volume":"2","author":"Linfante","year":"2010","journal-title":"J Neurointerv Surg"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1161\/STROKEAHA.110.589275","article-title":"Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group","volume":"41","author":"Vergouwen","year":"2010","journal-title":"Stroke"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000486458","article-title":"Abciximab (ReoPro) dosing strategy for the Management of Acute Intraprocedural Thromboembolic Complications during pipeline flow diversion treatment of intracranial aneurysms","volume":"7","author":"Lin","year":"2018","journal-title":"Interv Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00234-008-0457-8","article-title":"Abciximab for thrombolysis during intracranial aneurysm coiling","volume":"50","author":"Gralla","year":"2008","journal-title":"Neuroradiology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.3174\/ajnr.A716","article-title":"Intraarterial administration of abciximab for thromboembolic events occurring during aneurysm coil placement","volume":"24","author":"Mounayer","year":"2003","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1227\/NEU.0b013e3181f8d1db","article-title":"Abciximab treatment modalities for thromboembolic events related to aneurysm coiling","volume":"67","author":"Aggour","year":"2010","journal-title":"Neurosurgery"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.surneu.2005.08.024","article-title":"The use of abciximab in the treatment of acute cerebral thromboembolic events during neuroendovascular procedures","volume":"65","author":"Velat","year":"2006","journal-title":"Surg Neurol"},{"key":"ref14","first-page":"1744","article-title":"Abciximab in patients with ruptured intracranial aneurysms","volume":"26","author":"Aviv","year":"2005","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref15","first-page":"1147","article-title":"Thrombus formation during intracranial aneurysm coil placement: treatment with intra-arterial abciximab","volume":"25","author":"Song","year":"2004","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref16","first-page":"1764","article-title":"Use of abciximab for mediation of thromboembolic complications of endovascular therapy","volume":"22","author":"Cloft","year":"2001","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1097\/00006123-200204000-00045","article-title":"Management of intraprocedural arterial thrombus in cerebral aneurysm embolization with abciximab: technical case report","volume":"50","author":"Alexander","year":"2002","journal-title":"Neurosurgery"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.surneu.2003.10.045","article-title":"Intravenous abciximab for parent vessel thrombus during basilar apex aneurysm coil embolization: case report and literature review","volume":"62","author":"Bendok","year":"2004","journal-title":"Surg Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.wneu.2017.01.023","article-title":"Intra-arterial use of Abciximab in thromboembolic complications associated with cerebral aneurysm coiling: the London Ontario experience","volume":"100","author":"Martinez-Perez","year":"2017","journal-title":"World Neurosurg"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"6721","DOI":"10.1038\/s41598-023-33798-5","article-title":"Predictive validity of the prognosis on admission aneurysmal subarachnoid haemorrhage scale for the outcome of patients with aneurysmal subarachnoid haemorrhage","volume":"13","author":"Nguyen","year":"2023","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/s41467-024-46015-2","article-title":"Diagnosis and management of subarachnoid haemorrhage","volume":"15","author":"Thilak","year":"2015","journal-title":"Nat Commun"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3174\/ajnr.A3501","article-title":"Intra-arterial infusion of a glycoprotein IIb\/IIIa antagonist for the treatment of thromboembolism during coil embolization of intracranial aneurysm: a comparison of abciximab and tirofiban","volume":"34","author":"Jeong","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/19714009231166090","article-title":"Glycoprotein IIb\/IIIa inhibitors in the treatment of thromboembolic events related to endovascular treatment of cerebral aneurysms-systematic review and meta-analysis","volume":"37","author":"Hasanpour","year":"2024","journal-title":"Neuroradiol J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.3174\/ajnr.A1253","article-title":"Abciximab for treatment of thromboembolic complications during endovascular coiling of intracranial aneurysms","volume":"29","author":"Jones","year":"2008","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3174\/ajnr.A0641","article-title":"Effect of antiplatelet therapy on thromboembolic complications of elective coil embolization of cerebral aneurysms","volume":"28","author":"Yamada","year":"2007","journal-title":"AJNR Am J Neuroradiol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1573247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T04:10:28Z","timestamp":1750824628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1573247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":25,"alternative-id":["10.3389\/fneur.2025.1573247"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1573247","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"article-number":"1573247"}}